These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 30062539)

  • 1. Morphological, Stability, and Hypoglycemic Effects of New Gliclazide-Bile Acid Microcapsules for Type 1 Diabetes Treatment: the Microencapsulation of Anti-diabetics Using a Microcapsule-Stabilizing Bile Acid.
    Mathavan S; Chen-Tan N; Arfuso F; Al-Salami H
    AAPS PharmSciTech; 2018 Oct; 19(7):3009-3018. PubMed ID: 30062539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comprehensive study of novel microcapsules incorporating gliclazide and a permeation enhancing bile acid: hypoglycemic effect in an animal model of Type-1 diabetes.
    Mathavan S; Chen-Tan N; Arfuso F; Al-Salami H
    Drug Deliv; 2016 Oct; 23(8):2869-2880. PubMed ID: 26610261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Designing anti-diabetic β-cells microcapsules using polystyrenic sulfonate, polyallylamine, and a tertiary bile acid: Morphology, bioenergetics, and cytokine analysis.
    Mooranian A; Negrulj R; Al-Salami H; Morahan G; Jamieson E
    Biotechnol Prog; 2016 Mar; 32(2):501-9. PubMed ID: 26748789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of a novel bile acid-based delivery platform for microencapsulated pancreatic β-cells.
    Mooranian A; Negrulj R; Arfuso F; Al-Salami H
    Artif Cells Nanomed Biotechnol; 2016; 44(1):194-200. PubMed ID: 25014218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel artificial cell microencapsulation of a complex gliclazide-deoxycholic bile acid formulation: a characterization study.
    Mooranian A; Negrulj R; Chen-Tan N; Al-Sallami HS; Fang Z; Mukkur T; Mikov M; Golocorbin-Kon S; Fakhoury M; Arfuso F; Al-Salami H
    Drug Des Devel Ther; 2014; 8():1003-12. PubMed ID: 25114507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of the bile acid chenodeoxycholic acid in the targeted oral delivery of the anti-diabetic drug gliclazide, and its applications in type 1 diabetes.
    Mathavan S; Chen-Tan N; Arfuso F; Al-Salami H
    Artif Cells Nanomed Biotechnol; 2016 Sep; 44(6):1508-19. PubMed ID: 26212118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-Loading Dose of Microencapsulated Gliclazide Formulation Exerted a Hypoglycaemic Effect on Type 1 Diabetic Rats and Incorporation of a Primary Deconjugated Bile Acid, Diminished the Hypoglycaemic Antidiabetic Effect.
    Golocorbin-Kon S; Calasan J; Milijasevic B; Vukmirovic S; Lalic-Popovic M; Mikov M; Al-Salami H
    Eur J Drug Metab Pharmacokinet; 2017 Dec; 42(6):1005-1011. PubMed ID: 28547295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An advanced microencapsulated system: a platform for optimized oral delivery of antidiabetic drug-bile acid formulations.
    Mooranian A; Negrulj R; Mathavan S; Martinez J; Sciarretta J; Chen-Tan N; Mukkur TK; Mikov M; Lalic-Popovic M; Stojancevic M; Golocorbin-Kon S; Al-Salami H
    Pharm Dev Technol; 2015; 20(6):702-9. PubMed ID: 24798888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Release and swelling studies of an innovative antidiabetic-bile acid microencapsulated formulation, as a novel targeted therapy for diabetes treatment.
    Mooranian A; Negrulj R; Al-Sallami HS; Fang Z; Mikov M; Golocorbin-Kon S; Fakhoury M; Arfuso F; Al-Salami H
    J Microencapsul; 2015; 32(2):151-6. PubMed ID: 25265061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of a tertiary bile acid, taurocholic acid, on the morphology and physical characteristics of microencapsulated probucol: potential applications in diabetes: a characterization study.
    Mooranian A; Negrulj R; Arfuso F; Al-Salami H
    Drug Deliv Transl Res; 2015 Oct; 5(5):511-22. PubMed ID: 26242686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diabetes development increased concentrations of the conjugated bile acid, taurocholic acid in serum, while treatment with microencapsulated-taurocholic acid exerted no hypoglycaemic effects.
    Mathavan S; Mikov M; Golocorbin-Kon S; Al-Salami H
    Eur J Pharm Sci; 2017 Aug; 106():1-9. PubMed ID: 28529037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral gavage of nano-encapsulated conjugated acrylic acid-bile acid formulation in type 1 diabetes altered pharmacological profile of bile acids, and improved glycaemia and suppressed inflammation.
    Mooranian A; Zamani N; Ionescu CM; Takechi R; Luna G; Mikov M; Goločorbin-Kon S; Kovačević B; Al-Salami H
    Pharmacol Rep; 2020 Apr; 72(2):368-378. PubMed ID: 32048259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Swelling, mechanical strength, and release properties of probucol microcapsules with and without a bile acid, and their potential oral delivery in diabetes.
    Negrulj R; Mooranian A; Chen-Tan N; Al-Sallami HS; Mikov M; Golocorbin-Kon S; Fakhoury M; Watts GF; Arfuso F; Al-Salami H
    Artif Cells Nanomed Biotechnol; 2016 Aug; 44(5):1290-7. PubMed ID: 25811999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The incorporation of water-soluble gel matrix into bile acid-based microcapsules for the delivery of viable β-cells of the pancreas, in diabetes treatment: biocompatibility and functionality studies.
    Mooranian A; Negrulj R; Al-Salami H
    Drug Deliv Transl Res; 2016 Feb; 6(1):17-23. PubMed ID: 26671765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development, optimization, and anti-diabetic activity of gliclazide-loaded alginate-methyl cellulose mucoadhesive microcapsules.
    Pal D; Nayak AK
    AAPS PharmSciTech; 2011 Dec; 12(4):1431-41. PubMed ID: 22038475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Effects of Ionic Gelation- Vibrational Jet Flow Technique in Fabrication of Microcapsules Incorporating β-cell: Applications in Diabetes.
    Mooranian A; Negrulj R; Al-Salami H
    Curr Diabetes Rev; 2017; 13(1):91-96. PubMed ID: 26710877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Innovative Microcapsules for Pancreatic β-Cells Harvested from Mature Double-Transgenic Mice: Cell Imaging, Viability, Induced Glucose-Stimulated Insulin Measurements and Proinflammatory Cytokines Analysis.
    Mooranian A; Tackechi R; Jamieson E; Morahan G; Al-Salami H
    Pharm Res; 2017 Jun; 34(6):1217-1223. PubMed ID: 28289997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multicompartmental, multilayered probucol microcapsules for diabetes mellitus: Formulation characterization and effects on production of insulin and inflammation in a pancreatic β-cell line.
    Mooranian A; Negrulj R; Arfuso F; Al-Salami H
    Artif Cells Nanomed Biotechnol; 2016 Nov; 44(7):1642-53. PubMed ID: 26377035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The biological effects of the hypolipidaemic drug probucol microcapsules fed daily for 4 weeks, to an insulin-resistant mouse model: potential hypoglycaemic and anti-inflammatory effects.
    Mooranian A; Negrulj R; Takechi R; Mamo J; Al-Sallami H; Al-Salami H
    Drug Deliv Transl Res; 2018 Jun; 8(3):543-551. PubMed ID: 29313296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and development of gliclazide mucoadhesive microcapsules: in vitro and in vivo evaluation.
    Prajapati SK; Tripathi P; Ubaidulla U; Anand V
    AAPS PharmSciTech; 2008; 9(1):224-30. PubMed ID: 18446485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.